“Switching from Dupilumab to Upadacitinib in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab: Efficacy and Safety Results from the Phase 3b 4 LEVEL UP Study”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s451. Accessed April 18, 2026. https://skin.dermsquared.com/skin/article/view/3041.